Generic Medicine Info
Indications and Dosage
Treatment and prophylaxis of relapse of Plasmodium vivax malaria
Adult: 25 mg once daily for 7 days. To be used in comjunction with chloroquine.
Rheumatoid arthritis; systemic lupus erythematosus. Co-administration of drugs known to cause haemolysis.
Special Precautions
Exercise caution while administering bulaquine to patients suffering from G6PD deficiency. Pregnancy and lactation, children.
Drug Interactions
Specific studies with other drugs have not been undertaken except with chloroquine where it was concurrently used in the phase II/III clinical trials without any adverse effects.
Description: Bulaquine is a new generation of 8-aminoqinoline derivative antimalarial used in managing P. vivax infection. It reportedly inhibits protein synthesis in protozoa and polymerization of amino acids by the plasmodia. When co-administered with chloroquine, malarial is treated witho significant relapse episodes. Compared to primaquine, it requires lesser treatment days and it has better tolerance profile in patients with G6PD (G6PDH) deficiency.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Bulaquine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in